Form 4: Boston Scientific Executive Reports Routine Stock Transactions Following RSU Vesting

Vance R. Brown, SVP, GC and Corporate Secretary of Boston Scientific Corp., reported the acquisition of 4,036 shares of common stock through RSU vesting and the disposition of 1,952 shares for tax withholding.

Summary

• Vance R. Brown, the Senior Vice President, General Counsel, and Corporate Secretary of Boston Scientific Corp. (BSX), reported stock transactions on July 1, 2025.
• Acquired 4,036 shares of Boston Scientific common stock upon the vesting of Restricted Stock Units (RSUs).
• Disposed of 1,952 shares of common stock at a price of $104.78 per share to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, beneficial ownership of common stock is 33,451 shares.
• Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
• The shares of common stock from RSUs are issued to the reporting person in four equal annual installments, which began on July 1, 2022, the first anniversary of the grant date.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. This is a routine insider transaction (Form 4) indicating RSU vesting and tax-related sales. It's positive in that it shows an executive's equity compensation vesting, aligning their interests with shareholders, but it's not a strong indicator of company performance or future prospects.

Positives

• Vesting of Restricted Stock Units indicates the fulfillment of executive compensation, aligning the executive's interests with long-term shareholder value.
• The executive's continued beneficial ownership of 33,451 shares demonstrates ongoing equity alignment with the company's performance.

Negatives

• The disposition of 1,952 shares, even for tax purposes, results in a reduction of the executive's direct beneficial ownership.

Future Outlook

The document details past and current transactions related to executive compensation, specifically RSU vesting. It does not provide forward-looking statements or guidance on company performance or strategic outlook.

Industry Context

This Form 4 filing is a routine disclosure of insider stock transactions, common across all publicly traded companies. It reflects standard executive compensation practices within the medical technology industry, where equity awards like RSUs are frequently used to align executive interests with shareholder value.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of executive compensation is a common practice across the medical device and broader healthcare industry, aligning executive incentives with long-term company performance, similar to practices at Medtronic (MDT) and Abbott Laboratories (ABT).
• The disposition of shares to cover tax obligations upon RSU vesting is a standard procedure for equity compensation, observed in companies comparable to Boston Scientific, such as Johnson & Johnson (JNJ) and Stryker Corporation (SYK).
• The reported transaction volume of 4,036 shares acquired and 1,952 shares disposed is typical for individual executive compensation events, not indicative of a major strategic shift or large-scale insider selling/buying program.

Stakeholder Impact

• Shareholders: The vesting of RSUs and subsequent tax-related sale by a key executive is a routine event and generally has minimal direct impact on the broader shareholder base, though it reflects ongoing executive compensation practices.
• Employees: No direct impact on employees beyond the executive.

Next Steps

• Future annual installments of Restricted Stock Units are expected to vest on their respective anniversaries of the grant date (July 1st).

Key Dates

Recommendation

Keywords

Boston Scientific, BSX, Form 4, Insider Trading, Restricted Stock Units, RSU, Stock Vesting, Executive Compensation, Vance R Brown, Common Stock